Stability of Propranolol Hydrochloride in SyrSpend SF
Author(s): Geiger Christine M, Voudrie Mark A II, Sorenson Bridget
Issue: Nov/Dec 2012 - Volume 16, Number 6
View All Articles in Issue
Page(s): 513-515
Note: Electronic version includes errata or revisions.
Download in electronic PDF format for $75
Abstract: Propranolol hydrochloride is a beta blocker used to treat high blood pressure, abnormal heart rhythms, heart disease, pheochromocytoma, and certain types of tremors. Propranolol is marketed by Wyeth (now a part of Pfizer) and AstraZeneca under the brand names Inderal, Inderal LA, Avlocardyl, Deralin, Dociton, Inderalici, InnoPran XL, Sumial, Anaprilium, Bedranol SR (Sandoz). It is also available generically from several manufacturers. Propranolol hydrochloride is available as tablet, capsule, and oral liquid dosage forms in several strengths. Some patients are unable to tolerate oral tablets and capsules, challenging compounding pharmacies to seek alternative dosing options; namely oral solutions and suspensions. The objective of this study was to determine the stability of propranolol hydrochloride in SyrSpend SF. The drug was compounded into a 1-mg/mL suspension using SyrSpend SF and subsequently stored in a low actinic plastic prescription bottle at room temperature conditions. Six samples were assayed at each specific time point extending to 90 days by a stability-indicating high-performance liquid chromatography method. The method was validated for its specificity through forced-degradation studies. Based on the data collected, when protected from light at room temperature, the beyond-use date of propranolol hydrochloride in SyrSpend SF was shown to be at least 90 days.
Related Keywords: propranolol hydrochloride, nonselective beta-adrenergic receptor inhibitor, beta blocker, hypertension, high blood pressure, arrhythmias, heart disease, angina, tremor, chest pain, oral suspension, stability
Related Categories: EXCIPIENTS, PEER-REVIEWED, STABILITIES, COMPATIBILITIES, CARDIOLOGY, NEUROLOGY, STORAGE